# MUKnineb (NCT03188172)

> MUK Nine b: OPTIMUM Treatment Protocol

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03188172
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: University of Leeds
- Conditions: Multiple Myeloma
- Interventions: Cyclophosphamide; Bortezomib; Lenalidomide; Daratumumab; Dexamethasone; Melphalan; Filgrastim
- Enrollment: 95
- Primary outcome: Progression free survival

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=muknineb-nct03188172